Abuhattum, Shada
Kotzbeck, Petra
Schlüßler, Raimund
Harger, Alexandra
Ariza de Schellenberger, Angela
Kim, Kyoohyun
Escolano, Joan-Carles
Müller, Torsten
Braun, Jürgen
Wabitsch, Martin
Tschöp, Matthias
Sack, Ingolf
Brankatschk, Marko
Guck, Jochen
Stemmer, Kerstin
Taubenberger, Anna V.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BR54890/2-1, 419138906, 329628492)
Alexander von Humboldt-Stiftung (Humboldt-Professorship to J.G.)
H2020 Marie Skłodowska-Curie Actions (ITN BIOPOL (J.G.))
Volkswagen Foundation (92847)
Deutsche Krebshilfe (MSNZ)
European Regional Development Fund
Technische Universität Dresden
Article History
Received: 9 December 2021
Accepted: 23 May 2022
First Online: 20 June 2022
Competing interests
: T.M. is employed by the Bruker BioAFM GmbH. M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals, Cambridge, MA, USA; was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019; attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016; received funding for his research projects from Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019); was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S.p.A. (2016) and Bayer Pharma AG Berlin (2016); and, as former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018), and, since 2018, as CEO of Helmholtz Zentrum München, has been responsible for collaborations with a multitude of companies and institutions worldwide — in this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia worldwide, including but not limited to pharmaceutical corporations such as Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others; in this role, was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München as, for example, WO/2016/188932 A2 or WO/2017/194499 A1; and confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Other authors do not have any conflict of interest.